Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899155 · ClinicalTrials.gov registry record · Phase 2
Pan Tumor Rollover Study
A Phase 2 study of Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT03899155: Recruiting Phase 2 study of Cancer, sponsored by Bristol-Myers Squibb.
NCT03899155 is a Phase 2 study of Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899155, a Phase 2 study of Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Relatlimab
- DRUG Cabozantinib
- DRUG Trametinib
Study Locations (20)
California
- Innovative Clinical Research Institute - Lynwood
- Local Institution - San Francisco
- Local Institution - 0099 - San Francisco
Florida
- Florida Cancer Affiliates - Ocala
- Local Institution - Orlando
- Local Institution - 0024 - Tampa
Illinois
- Local Institution - 0105 - Chicago
- Local Institution - Maywood
- Local Institution - 0279 - Park Ridge
Kansas
- Local Institution - 0186 - Westwood
- Local Institution - 0165 - Wichita
Massachusetts
- Local Institution - 0039 - Boston
- Dana_Farber Cancer Institute (DFCI) - Boston
Alabama
- Local Institution - 0220 - Huntsville
Arizona
- University of Arizona College of Medicine - Tucson
Colorado
- Local Institution - 0233 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2029-08-25 |
| Phase | Phase 2 |
What NCT03899155 shows while recruiting
NCT03899155 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03899155 names 20 study sites across 12 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03899155 about?
NCT03899155 is a clinical study titled "Pan Tumor Rollover Study". Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
What is the current status of trial NCT03899155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,500 participants. The study started on 2020-05-05. Estimated completion is 2029-08-25.
What conditions does trial NCT03899155 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03899155?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Relatlimab (DRUG), Cabozantinib (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT03899155?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899155 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03899155's enrollment target sits among peer trials
1,500 68th of 615 higher than 545 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI